Literature DB >> 18835315

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

Marina De Filette1, Wouter Martens, Anouk Smet, Michael Schotsaert, Ashley Birkett, Patricia Londoño-Arcila, Walter Fiers, Xavier Saelens.   

Abstract

The extracellular domain of influenza A virus matrix protein 2 (M2e) is strongly conserved. Therefore, vaccines based on M2e can induce broad-spectrum immunity against influenza. We have mainly used recombinant virus-like particles derived from Hepatitis B virus core (HBc) as carrier for efficacious presentation of the M2e antigen. Here, we address whether pre-existing HBc-specific immunity interferes with the protective immune response obtained by M2e-HBc vaccination. Anti-HBc antibodies were induced by immunizing mice with unsubstituted HBc virus-like particles in the presence of two different adjuvants. We demonstrate that pre-existing HBc-specific antibodies affect neither the induction of M2e-specific antibody responses to vaccination with M2e-HBc particles, nor the protective efficacy of the resulting response. These results suggest that vaccination with M2e-HBc can induce protective anti-M2e antibodies even in anti-HBc positive individuals. The implications of these findings are discussed in the context of the clinical development of an M2e-based universal influenza vaccine, which recently successfully completed a Phase I trial.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835315     DOI: 10.1016/j.vaccine.2008.09.038

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  38 in total

Review 1.  Influenza A viruses: why focusing on M2e-based universal vaccines.

Authors:  Seyyed Mahmoud Ebrahimi; Majid Tebianian
Journal:  Virus Genes       Date:  2010-11-17       Impact factor: 2.332

2.  A candidate dual vaccine against influenza and noroviruses.

Authors:  Ming Xia; Ming Tan; Chao Wei; Weiming Zhong; Leyi Wang; Monica McNeal; Xi Jiang
Journal:  Vaccine       Date:  2011-08-11       Impact factor: 3.641

Review 3.  Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design.

Authors:  Sinthujan Jegaskanda; Hillary A Vanderven; Adam K Wheatley; Stephen J Kent
Journal:  Hum Vaccin Immunother       Date:  2017-03-23       Impact factor: 3.452

4.  Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens.

Authors:  Byung-Min Song; Hyun-Mi Kang; Eun-Kyoung Lee; Suk Chan Jung; Min-Chul Kim; Yu-Na Lee; Sang-Moo Kang; Youn-Jeong Lee
Journal:  Vaccine       Date:  2015-12-12       Impact factor: 3.641

Review 5.  Developments of subunit and VLP vaccines against influenza A virus.

Authors:  Ma-ping Deng; Zhi-hong Hu; Hua-lin Wang; Fei Deng
Journal:  Virol Sin       Date:  2012-06-09       Impact factor: 4.327

6.  A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2.

Authors:  Pierre-Louis Hervé; Mariam Raliou; Christiane Bourdieu; Catherine Dubuquoy; Agnès Petit-Camurdan; Nicolas Bertho; Jean-François Eléouët; Christophe Chevalier; Sabine Riffault
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

7.  Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus.

Authors:  Wenqian Tao; Katherine S Ziemer; Harvinder S Gill
Journal:  Nanomedicine (Lond)       Date:  2013-07-05       Impact factor: 5.307

Review 8.  Adjuvant formulations for virus-like particle (VLP) based vaccines.

Authors:  Velasco Cimica; Jose M Galarza
Journal:  Clin Immunol       Date:  2017-08-03       Impact factor: 3.969

Review 9.  Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

Authors:  Michael Schotsaert; Marina De Filette; Walter Fiers; Xavier Saelens
Journal:  Expert Rev Vaccines       Date:  2009-04       Impact factor: 5.217

10.  Immunogenicity and protective efficacy of recombinant M2e.Hsp70c (Hsp70(359-610)) fusion protein against influenza virus infection in mice.

Authors:  Hamidreza Attaran; Hassan Nili; Majid Tebianian
Journal:  Virol Sin       Date:  2014-08-18       Impact factor: 4.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.